Medical Advocates
Pegylated Interferons
    Main Page

New and Noteworthy
 Miscellaneous Studies
 General HBV Studies
 General HCV Studies
General HIV/HCV Studies
Peg Interferon Alfa 2a
Peg Interferon Alfa 2b



 

  
Peg Inf alfa 2a Main Main New/Newsworthy  Home Page
Last Update:  October 11, 2011
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
October 2011
 

September 2011
 
Miscellaneous Studies
     
    Journal Papers, Abstracts, and Commentaries
 
 
Peginterferon/ribavirin treatment achieves a higher compliance rate than interferon/ribavirin
combination in patients chronically infected with HCV on methadone maintenance.
 Dimitroulopoulos D, Petroulaki E, Manolakopoulos S, et al
Eur J Gastroenterol Hepatol. 2009 Dec;21(12):1407-12.
 Abstract

Comparison of biochemical safety between PEG-IFN alpha-2a and PEG-IFN alpha-2b.
Katano Y, Kumada T, Nakano I, et al
 Hepatogastroenterology. 2009 Mar-Apr;56(90):485-91
 Abstract
 
General HBV Studies
     
    Journal Papers, Abstracts, and Commentaries
 
  Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who
have failed treatment.
Sarin SK, Kumar M, Hissar S, Sharma BC.
Hepatobiliary Pancreat Dis Int. 2006 Aug;5(3):374-80
 Abstract
 
Pegylated interferon alpha in the treatment of chronic hepatitis B in HBe negative patients
Pawlowska M, Halota W.
Przegl Epidemiol. 2006;60(1):105-8.
 Abstract
 
Pegylated interferons for chronic hepatitis B
Craxi A, Cooksley WG.
Antiviral Res. 2003 Oct;60(2):87-9.
 Abstract
General HIV/HCV Studies
     
     Journal Papers, Abstracts, and Commentaries
 
 
Randomized Trial Comparing Dose Reduction and Growth Factor Supplementation for Management of Hematological Side Effects in HIV/HCV Patients Receiving Pegylated-Interferon and Ribavirin.
 Talal AH, Liu RC, Zeremski M, et al
J Acquir Immune Defic Syndr. 2011 Aug 26.
 Abstract

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV
co-infection: a systematic review and economic evaluation.
 Hartwell D, Jones J, Baxter L, Shepherd J.
Health Technol Assess. 2011 Apr;15(17):1-210.
 Abstract

Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon
and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
 Rivero-Juárez A, Mira JA, Pérez-Camacho I,  et al
 J Antimicrob Chemother. 2011 Mar 17.
 Abstract

Differences in liver fibrosis and response to pegylated interferon plus ribavirin in
HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
 Maida I, Martin-Carbonero L, Sotgiu G, et al
J Viral Hepat. 2010 Jan 18
 Abstract

HIV/Hepatitis C Virus-Coinfected Virologic Responders to Pegylated Interferon
and Ribavirin Therapy More Frequently Incur Interferon-Related Adverse Events
Than Nonresponders Do.
 Osinusi A, Rasimas JJ, Bishop R, et al
J Acquir Immune Defic Syndr. 2010 Jan 23
 Abstract

Alpha-interferon versus peg-interferon associated to ribavirin in the treatment of genotype 1
hepatitis C virus and human immunodeficiency virus coinfected patients]
Almeida PR, Tovo CV, Rigo JO, et al
 Arq Gastroenterol. 2009 Apr-Jun;46(2):132-7.
 Abstract

Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients
receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside
analogue backbone.
 Mira JA, López-Cortés LF, Barreiro P,  et al 
Antimicrob Chemother. 2008 Oct 13
 Abstract
 
HCV RNA in peripheral blood cell subsets in HCV-HIV coinfected patients at the end of PegIFN/RBV treatment
is associated with virologic relapse.
 de Felipe B, Leal M, Soriano-Sarabia N, et al 
J Viral Hepat. 2008 Aug 28.
 Abstract

Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated
with abacavir.
 Vispo E, Barreiro P, Pineda JA, et al 
Antivir Ther. 2008;13(3):429-37
 Abstract

Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected
patients failing a previous standard interferon-based regimen.
 Crespo M, Mira JA, Pineda JA, et al  
 J Antimicrob Chemother. 2008 Jun 21.
 Abstract

The use of trough ribavirin concentration to predict sustained virological response and
haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and
pegylated interferon.
 Marucco DA, de Requena DG, Bonora S, Tet al 
J Antimicrob Chemother. 2008 Jan 31
Abstract
 
Baseline CD4 Cell Count and Outcome of Pegylated Interferon Plus Ribavirin Therapy in
HIV/Hepatitis C Virus-Coinfected Patients.
 Valerio L, Yazdanpanah Y, Poizot-Martin I, et al  
J Acquir Immune Defic Syndr. 2007 Oct 11
Abstract
 
Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection:
a research synthesis.
 Shire NJ, Welge JA, Sherman KE.
J Viral Hepat. 2007 Apr;14(4):239-48.
 Abstract
 
     Conference Reports, Abstracts, and Posters 
 
 
POSTER
 Effect of Accompanying Antiretroviral Drugs on Virologic Response to PEG-IFN and Ribavirin
in HIV/HCV-Co-infected Patients
J Berenguer, M von Wichmann, C Quereda, et al
 (17th CROI)
PDF Poster     Abstract
 
POSTER
 Interleukin 28 B Genotype Is a Potent Predictor of Response to Therapy with Pegylated
Interferon plus Ribavirin in HIV/HCV Co-infected Patients
 J Pineda, A Caruz, Á Camacho, et al
 (17th CROI)
PDF Poster     Abstract

Insulin Resistance Impairs Sustained Virologic Response to Interferon plus Ribavirin
in HIV/HCV-co-infected Patients
 P Ryan, S Resino, P Miralles, et al 
(16 CROI
 Abstract

POSTER
 Duration of Viral HCV Supression as a Predictor of Sustained Virological Response in
HIV/HCV-co-infected Patients Treated with Pegylated-Interferon + Ribavirin
 C Quereda, F Ferrere, A Moreno, et al 
(16 CROI)
 PDF Poster     Abstract

Effect of a Widely Used HCV Therapy on the Current Distribution of HCV Genotypes in a Large Cohort of
HIV/HCV-co-infected Patients in Spain
 E Vispo, A Madejon, P Tuma, et al
 (16 CROI)
 Abstract
 
POSTER
 Efficacy of Pegylated Interferon + Ribavirin Treatment in HIV/HCV-co-infected Patients
Receiving Abacavir + Lamivudine or Tenofovir + either Lamivudine or Emtricitabine as
Nucleoside Analogue Backbone
 J Mira, L Lopez-Cortes, P Barreiro, et al
(15th CROI)
 PDF Poster     Abstract

POSTER
Antiretroviral Regimens including Tenofovir or Stavudine + Lamivudine as NRTI Backbone
Are Associated with Higher Sustained Virological Response Rate to Pegylated Interferon
and Ribavirin Treatment in HIV/HCV-co-infected Patients
 J. Mira, R Carrillo-Gómez, A Gutierrez
 15th CROI
PDF Poster     Abstract
General HDV Studies
     
    Journal Papers, Abstracts, and Commentaries
 
  Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon,
tenofovir and emtricitabine.
Mansour W, Ducancelle A, Le Gal F,  et al 
J Clin Virol. 2009 Nov 12.
 Abstract

Peg Inf alfa 2a Main Main New/Newsworthy  Home Page

Pegylated Interferons